Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

Fig. 1

Markers of disease activity in patients with Crohn’s disease (CD). Changes in Harvey–Bradshaw (HB) scores, perianal disease activity index (PDAI) and biochemical markers (C-reactive protein and haemoglobin levels) of disease activity during treatment of CD patients with infliximab (IFX) measured at the time of IFX initiation (0) and at the fourth infusion (14). Rem remission, Res responder, NRes non-responder. * P < 0.05; *** P < 0.001; **** P < 0.0001

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us